For instance, therapies like EREG monoclonal antibodies or selective PI3K/Akt inhibitors, many of which are in clinical development, could be repurposed for glioma subtypes characterized by low FTO expression (Li et al., 2016; Wick et al., 2011; Roth et al., 2014). The gene discussed is FTO; the disease is central nervous system cancer.